DE10209985A1 - Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze - Google Patents

Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Info

Publication number
DE10209985A1
DE10209985A1 DE10209985A DE10209985A DE10209985A1 DE 10209985 A1 DE10209985 A1 DE 10209985A1 DE 10209985 A DE10209985 A DE 10209985A DE 10209985 A DE10209985 A DE 10209985A DE 10209985 A1 DE10209985 A1 DE 10209985A1
Authority
DE
Germany
Prior art keywords
methyl
pharmaceutical composition
acid
composition according
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10209985A
Other languages
German (de)
English (en)
Inventor
Ulrich Brauns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10209985A priority Critical patent/DE10209985A1/de
Priority to MEP-2008-507A priority patent/ME00325B/me
Priority to EP07115663A priority patent/EP1870100B1/de
Priority to PT03743368T priority patent/PT1485094E/pt
Priority to EP03743368.7A priority patent/EP1485094B2/de
Priority to BRPI0306559A priority patent/BRPI0306559B8/pt
Priority to EA200401136A priority patent/EA009664B1/ru
Priority to IL16386303A priority patent/IL163863A0/xx
Priority to CN200910149806A priority patent/CN101632668A/zh
Priority to NZ546367A priority patent/NZ546367A/en
Priority to PL370517A priority patent/PL210862B1/pl
Priority to CNB038054736A priority patent/CN100528157C/zh
Priority to AT07115663T priority patent/ATE540943T1/de
Priority to JP2003572573A priority patent/JP3866715B2/ja
Priority to UA20041008096A priority patent/UA81760C2/uk
Priority to CA2476054A priority patent/CA2476054C/en
Priority to NZ535663A priority patent/NZ535663A/en
Priority to SI200332190T priority patent/SI1485094T2/sl
Priority to UAA200708221A priority patent/UA95601C2/uk
Priority to YU79204A priority patent/RS52088B/sr
Priority to SG200504113-2A priority patent/SG146435A1/en
Priority to MXPA04008542A priority patent/MXPA04008542A/es
Priority to ES07115663T priority patent/ES2380704T3/es
Priority to KR1020047013919A priority patent/KR101005716B1/ko
Priority to DK07115663.2T priority patent/DK1870100T3/da
Priority to DK03743368.7T priority patent/DK1485094T4/da
Priority to SI200332126T priority patent/SI1870100T1/sl
Priority to AU2003210400A priority patent/AU2003210400B8/en
Priority to PCT/EP2003/002141 priority patent/WO2003074056A1/de
Priority to PL394601A priority patent/PL212566B1/pl
Priority to PT07115663T priority patent/PT1870100E/pt
Priority to ES03743368T priority patent/ES2390661T5/es
Priority to MYPI20030780A priority patent/MY143734A/en
Priority to PE2003000211A priority patent/PE20030889A1/es
Priority to TW092105051A priority patent/TWI293879B/zh
Priority to UY27694A priority patent/UY27694A1/es
Priority to US10/383,198 priority patent/US20030181488A1/en
Priority to ARP030100779A priority patent/AR042861A1/es
Publication of DE10209985A1 publication Critical patent/DE10209985A1/de
Priority to NO20042361A priority patent/NO326918B1/no
Priority to ZA2004/06071A priority patent/ZA200406071B/en
Priority to IL163863A priority patent/IL163863A/en
Priority to HRP20040807AA priority patent/HRP20040807B1/hr
Priority to EC2004005331A priority patent/ECSP045331A/es
Priority to CO04099830A priority patent/CO5611149A2/es
Priority to HK05110948.7A priority patent/HK1078792A1/xx
Priority to US11/381,890 priority patent/US9925174B2/en
Priority to JP2006218435A priority patent/JP2007056018A/ja
Priority to JP2006218436A priority patent/JP4953727B2/ja
Priority to NO20081304A priority patent/NO332209B1/no
Priority to ARP090102391A priority patent/AR072385A2/es
Priority to CL2009001915A priority patent/CL2009001915A1/es
Priority to IL209368A priority patent/IL209368A/en
Priority to CY20121100346T priority patent/CY1112796T1/el
Priority to LU92025C priority patent/LU92025I2/fr
Priority to DE201212000047 priority patent/DE122012000047I1/de
Priority to CY2012020C priority patent/CY2012020I2/el
Priority to CY20121100894T priority patent/CY1113158T1/el
Priority to CY2012031C priority patent/CY2012031I2/el
Priority to LU92117C priority patent/LU92117I2/fr
Priority to NO2013001C priority patent/NO2013001I2/no
Priority to US14/489,892 priority patent/US20150005350A1/en
Priority to US15/946,096 priority patent/US20180221359A1/en
Priority to US16/380,161 priority patent/US20190231766A1/en
Priority to US16/694,091 priority patent/US20200085807A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE10209985A 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze Withdrawn DE10209985A1 (de)

Priority Applications (64)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
MEP-2008-507A ME00325B (me) 2002-03-07 2003-03-03 Oblik za oralnu primjenu etilestra 3-[(2-{[4-(heksiloksikarbonjlaminoimino-metil)-fenilamino]-metil}-1-metil-ih-benzimidazol-5-carbonil)-piridin- 2-yl-amino]-propionsk kisjeline i njihovih soli
EP07115663A EP1870100B1 (de) 2002-03-07 2003-03-03 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester Methansulfonat
PT03743368T PT1485094E (pt) 2002-03-07 2003-03-03 Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais
EP03743368.7A EP1485094B2 (de) 2002-03-07 2003-03-03 Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
BRPI0306559A BRPI0306559B8 (pt) 2002-03-07 2003-03-03 composição farmacêutica para aplicação oral para mesilato de etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seu processo de preparação
EA200401136A EA009664B1 (ru) 2002-03-07 2003-03-03 Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
IL16386303A IL163863A0 (en) 2002-03-07 2003-03-03 Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
CN200910149806A CN101632668A (zh) 2002-03-07 2003-03-03 口服药物组合物
NZ546367A NZ546367A (en) 2002-03-07 2003-03-03 Methanesulphonate salt of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate to be administered orally
PL370517A PL210862B1 (pl) 2002-03-07 2003-03-03 Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji
CNB038054736A CN100528157C (zh) 2002-03-07 2003-03-03 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型
AT07115663T ATE540943T1 (de) 2002-03-07 2003-03-03 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
JP2003572573A JP3866715B2 (ja) 2002-03-07 2003-03-03 ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態
UA20041008096A UA81760C2 (uk) 2002-03-07 2003-03-03 Фармацевтична композиція для перорального застосування етилового ефіру 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1-метил-1н-бензімідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти та спосіб її одержання
CA2476054A CA2476054C (en) 2002-03-07 2003-03-03 Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
NZ535663A NZ535663A (en) 2002-03-07 2003-03-03 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
SI200332190T SI1485094T2 (sl) 2002-03-07 2003-03-03 Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli
UAA200708221A UA95601C2 (uk) 2002-03-07 2003-03-03 Метансульфонат етилового ефіру 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1метил-1н-бензимідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти та фармацевтична композиція, яка його містить
YU79204A RS52088B (sr) 2002-03-07 2003-03-03 Oblik za oralnu primenu etilestra 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionske kiseline i njegovih soli
SG200504113-2A SG146435A1 (en) 2002-03-07 2003-03-03 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl- amino] propionic acid ethyl ester to be administered orally
MXPA04008542A MXPA04008542A (es) 2002-03-07 2003-03-03 Forma de administracion para aplicacion oral, de ester etilico de acido 3-[(2- {[4 -(hexiloxicarbonilamino -imino-metil) -finilamino] -metil}-1 -metil- 1h-bencimidazol -5-carbonil) -piridin-2 -il-amino]- propionico y sales de la misma.
ES07115663T ES2380704T3 (es) 2002-03-07 2003-03-03 Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
KR1020047013919A KR101005716B1 (ko) 2002-03-07 2003-03-03 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
DK07115663.2T DK1870100T3 (da) 2002-03-07 2003-03-03 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester-methansulfonat
DK03743368.7T DK1485094T4 (da) 2002-03-07 2003-03-03 Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
SI200332126T SI1870100T1 (sl) 2002-03-07 2003-03-03 Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
AU2003210400A AU2003210400B8 (en) 2002-03-07 2003-03-03 Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-imino -methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
PCT/EP2003/002141 WO2003074056A1 (de) 2002-03-07 2003-03-03 Oral zu applizierende darreichungsform für 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen salze
PL394601A PL212566B1 (pl) 2002-03-07 2003-03-03 Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego
PT07115663T PT1870100E (pt) 2002-03-07 2003-03-03 Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo
ES03743368T ES2390661T5 (es) 2002-03-07 2003-03-03 Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales
MYPI20030780A MY143734A (en) 2002-03-07 2003-03-05 Administration form for the oral application of 3-[(2-<[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl>-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
PE2003000211A PE20030889A1 (es) 2002-03-07 2003-03-05 Forma de presentacion para administracion por via oral, para ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil} -1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino] - propionico y sus sales
TW092105051A TWI293879B (en) 2002-03-07 2003-03-06 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino -imino -methyl)-phenylamion]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
UY27694A UY27694A1 (es) 2002-03-07 2003-03-06 Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.
US10/383,198 US20030181488A1 (en) 2002-03-07 2003-03-06 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
ARP030100779A AR042861A1 (es) 2002-03-07 2003-03-07 Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales
NO20042361A NO326918B1 (no) 2002-03-07 2004-06-07 Farmasoytisk preparat og fremgangsmate for fremstilling derav.
ZA2004/06071A ZA200406071B (en) 2002-03-07 2004-07-29 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-methyl)-pheny-lamino -methyl-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]propionic acid ethyl ester to be administered orally
IL163863A IL163863A (en) 2002-03-07 2004-09-01 Pharmaceutical composition for oral administration of 3-[(2 -{[4- (hexyloxycarbonylamino- imino- methyl)-phenylamino]methyl}-1- methyl-1h- benzimidazol-5- carbonyl)- pyridin- 2- yl- amino] propionic acid ethyl ester
HRP20040807AA HRP20040807B1 (hr) 2002-03-07 2004-09-06 Oblik etil estera 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]-propionske kiseline i njegovih soli za oralnu aplikaciju
EC2004005331A ECSP045331A (es) 2002-03-07 2004-09-30 Forma de presentación para administración por vía oral, para éster etílico de ácido 3?[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-?bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico y sus sales
CO04099830A CO5611149A2 (es) 2002-03-07 2004-10-06 Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com
HK05110948.7A HK1078792A1 (en) 2002-03-07 2005-12-01 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl- amino] propionic acid ethyl ester to be administered orally
US11/381,890 US9925174B2 (en) 2002-03-07 2006-05-05 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
JP2006218435A JP2007056018A (ja) 2002-03-07 2006-08-10 ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル又はその塩を含む経口投与用医薬組成物
JP2006218436A JP4953727B2 (ja) 2002-03-07 2006-08-10 ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルメタンスルホン酸塩及びそれを含む医薬組成物
NO20081304A NO332209B1 (no) 2002-03-07 2008-03-12 Etyl-3-[(2-{[4-(heksyloksykarbonyl¬amino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]-propionat- metansulfonat
ARP090102391A AR072385A2 (es) 2002-03-07 2009-06-26 Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico y composicion farmaceutica para administracion por via oral que lo contiene
CL2009001915A CL2009001915A1 (es) 2002-03-07 2009-09-29 Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexilcarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico; util como antitrombotico (divisional de la solicitud cl 425-2003).
IL209368A IL209368A (en) 2002-03-07 2010-11-17 Ethylsulfonate Salt of Ethyl 3 - [(2– {4– (xyloxycarbonylamino – amino – methyl) –phenylamino] –methyl} –1 – methyl – H1– benzamideimzole – 5 – carbonyl) –pyridine – 2 – ile-amino] propionate and preparation Pharmacy containing it
CY20121100346T CY1112796T1 (el) 2002-03-07 2012-04-09 Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβοονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας
LU92025C LU92025I2 (fr) 2002-03-07 2012-06-20 Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
DE201212000047 DE122012000047I1 (de) 2002-03-07 2012-06-29 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino{-propionsaure-ethylester Methansulfonat.
CY2012020C CY2012020I2 (el) 2002-03-07 2012-07-10 Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας
CY20121100894T CY1113158T1 (el) 2002-03-07 2012-09-28 Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
CY2012031C CY2012031I2 (el) 2002-03-07 2012-12-14 Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
LU92117C LU92117I2 (fr) 2002-03-07 2012-12-19 Méthanesulfonate d'éthylester d'acide 3-[2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-proprionique
NO2013001C NO2013001I2 (no) 2002-03-07 2013-01-02 Dabigatran-etexilate og salter derav; spesielt dabigatran-etexilate-mesylate
US14/489,892 US20150005350A1 (en) 2002-03-07 2014-09-18 Administration of ethyl 3-[(2--1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US15/946,096 US20180221359A1 (en) 2002-03-07 2018-04-05 Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US16/380,161 US20190231766A1 (en) 2002-03-07 2019-04-10 Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US16/694,091 US20200085807A1 (en) 2002-03-07 2019-11-25 Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Publications (1)

Publication Number Publication Date
DE10209985A1 true DE10209985A1 (de) 2003-09-25

Family

ID=27771070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10209985A Withdrawn DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Country Status (4)

Country Link
CN (1) CN101632668A (uk)
DE (1) DE10209985A1 (uk)
UA (2) UA95601C2 (uk)
UY (1) UY27694A1 (uk)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2817000T1 (sl) 2012-02-21 2022-02-28 Towa Pharmaceutical Europe, S.L. Oralna farmacevtska sestava dabigatran eteksilata
CN102793699B (zh) * 2012-08-06 2014-06-04 严轶东 一种含有达比加群酯的药用组合物
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物

Also Published As

Publication number Publication date
UA81760C2 (uk) 2008-02-11
CN101632668A (zh) 2010-01-27
UA95601C2 (uk) 2011-08-25
UY27694A1 (es) 2003-10-31

Similar Documents

Publication Publication Date Title
EP1485094B2 (de) Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
DE10209982A1 (de) Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE69833490T2 (de) Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung
DE69832816T2 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DE69533470T2 (de) Aus mehreren einzeleinheiten zusammengesetztes pharmazeutisches präparat, das einen protonenpumpeninhibitor enthält
EP1689370B1 (de) VERFAHREN ZUR HERSTELLUNG EINER FESTEN, ORAL APPLIZIERBAREN PHARMAZEUTISCHEN ZUSAMMENSETZUNG Mit 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE69630286T2 (de) Aus mehreren einzeleinheiten zusammengesetzte dosierungsformen enthaltend einem protonen pumpen inhibitor
DE69631981T2 (de) Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
DE60100186T2 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
US20030181488A1 (en) Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP2037891B1 (de) Tablette enthaltend candesartan cilexetil
CH648484A5 (de) Pharmazeutische zubereitung eines festen medikamentmaterials.
EP0299211A1 (de) DHP-Manteltablette
DE69721749T2 (de) Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung
DE102008046650A1 (de) Quetiapin enthaltende Retardtablette
WO2010043408A2 (de) Mikroverkapseltes fesoterodin
DE102008037324A1 (de) Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
DE60030654T2 (de) Verwendung von Lasofoxifen
DE10209985A1 (de) Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE10245624A1 (de) Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
WO2011000518A1 (en) Pharmaceutical composition comprising desloratadine
EP1663162B1 (de) Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe
DE60205925T2 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisochinol-2-yl)-5-(2-pyridyl)chinazolin
DE10152469A1 (de) 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
EP1424068A1 (de) Verfahren zur Herstellung von Pellets, enthaltend ein tri- oder tetracyclisches Antidepressivum sowie diese Pellets enthaltende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
8141 Disposal/no request for examination